FDA: Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability

Federal Register

Mar 11, 2024

Notice from the Food and Drug Administration (FDA) announcing the revocation of one Emergency Use Authorization (EUA) issued to Eli Lilly and Co. (Lilly) for bamlanivimab and etesevimab administered together. The revocation is effective December 14, 2023.

COVID-19 · Legislation and regulations · Pharmacy and prescription drugs